Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: Results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan

Japanese Journal of Clinical Oncology

Volumn 44, Issue 6, 2014, Pages 541-546

  Yamaguchi, Kensei ^a   Watanabe, Toshiaki ^b   Satoh, Taroh ^c,d   Ishiguro, Megumi ^e   Izawa, Makiko ^f   Inoshiri, Shogo ^g   Sugihara, Kenichi ^e   Sakata, Yuh ^h  

^a SAITAMA CANCER CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KINKI UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f Bristol Myers KK   (Japan)

^g Merck Serono Co Ltd   (Japan)

^h Department of Radiology   (Japan)

Author keywords

Cetuximab; Chemotherapy; Colorectal cancer; Infusion reaction

Indexed keywords

ANTIHISTAMINIC AGENT; CETUXIMAB; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CANCER REGISTRY; COMBINATION CHEMOTHERAPY; DRUG SAFETY; FOLLOW UP; HUMAN; INCIDENCE; INFUSION RELATED REACTION; JAPAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MULTICENTER STUDY; PREMEDICATION; RECURRENT DISEASE; RISK FACTOR;

CETUXIMAB; CHEMOTHERAPY; COLORECTAL CANCER; INFUSION REACTION;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; JAPAN; MALE; MIDDLE AGED; PREMEDICATION; PROSPECTIVE STUDIES; REGISTRIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84901762525     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu049     Document Type: Article

References (16)

1. Rituxan® (rituximab). Package Insert. South San Francisco, CA:Genentech, Inc. (Revised: 04/2011).
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42.
3. Herceptin® (trastuzumab). Package Insert. South San Francisco, CA:Genentech, Inc. (Revised: 10/2010).
4. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001;61(Suppl 2):58-66.
5. Avastin® (bevacizumab). Package Insert. South San Francisco, CA:Genentech, Inc. (Revised: 12/2011).
6. Vectibix® (panitumumab). Package Insert. Thousand Oaks, CA: Amgen Inc. (Revised: 12/2011).
7. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9.
8. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
9. Ciardiello F, Tortora G. A novel approach in the treatment of cancer:targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
10. Erbitux® (cetuximab). Package Insert. New York, NY: ImClone Systems Incorporated. Princeton, NJ: Bristol-Myers Squibb Company. (Revised:01/2012).
11. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
12. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J ClinOncol 2008;26:2311-9.
13. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
14. Siena S, Glynne-Jones R, Adenis A, et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 2010;116:1827-37.
15. Wilke H, Glynne-Jones R, Thaler J, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan:MABEL Study. J Clin Oncol 2008;26:5335-43.
16. Ishiguro M, Watanabe T, Yamaguchi K, et al. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 2012;42:287-94.